A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Biomarkers, Tumor
  • Genomic Instability
  • Pancreatic Neoplasms
  • Precision Medicine

abstract

  • Irinotecan has minimal activity in biliary tree carcinomas, but is well tolerated with appropriate supportive care, and produces occasional objective responses.

publication date

  • June 5, 2001

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1023/A:1011135014895

PubMed ID

  • 11398883

Additional Document Info

start page

  • 501

end page

  • 4

volume

  • 12

number

  • 4